AT9283 is a potent inhibitor of several protein kinases, including Aurora A, Aurora B, Janus kinase 2 (JAK2), JAK3, and ABL. AT9283 potently inhibited proliferation and Jak2-related signalling in Jak2-dependent cell lines. The compound also demonstrated significant therapeutic potential in vivo in an ETV6-JAK2 (TEL-JAK2) murine leukaemia model.
Cell Experiment | |
---|---|
Cell lines | HCT 116 cells |
Preparation method | Primary HCT116 Cellular Assay. HCT 116 cells were cultured in DMEM + 10% FBS + GLUTAMAX I. Black 96-well flat bottomed (clear) tissue culture treated plates were seeded at 5 × 103 cells per well in 200 µL of medium and incubated for approximately 16 h at 37 °C in a humidified atmosphere of 5% CO2 in air. Cells were treated with test compound at nine different concentrations (spanning 1 nM to 10 µM, plus DMSO vehicle control) and then incubated for 72 h. Polyploidy morphological observations of the cells were then noted. The concentration of test compound required to produce a distinct polyploid phenotype was reported. |
Concentrations | 1 nM to 10 µM |
Incubation time | 72 h |
Animal Experiment | |
---|---|
Animal models | HCT116 Colon Carcinoma Cell Line Xenograft Model |
Formulation | 10% DMSO, 20% water, 70% hydroxypropyl--cyclodextrin (25% w/v aq) |
Dosages | 15 and 20mg/kg twice daily (b.i.d. × 2, q4d) × 5 |
Administration | intraperitoneal |
Molecular Weight | 381.43 |
Formula | C19H23N7O2 |
CAS Number | 896466-04-9 |
Solubility (25°C) | DMSO 61 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related Aurora Kinase Products |
---|
Aurora Kinases-IN-4
Aurora Kinases-IN-4 is a covalent and ATP competitive aurora kinase A inhibitor (IC50: 1.7 nM). |
Derrone
Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC50 values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity. |
CD532 hydrochloride
CD532 hydrochloride is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 hydrochloride also can directly interact with AURKA and induces a global conformational shift. CD532 hydrochloride can be used for the research of cancer. |
Aurora kinase inhibitor-2
Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively. |
AAPK-25
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.